PRA-rcd2 belongs to a group of retinal disorders known as rod-cone dysplasias, which involve abnormal development and degeneration of the retina’s photoreceptor cells. These cells include rods, which enable vision in dim light, and cones, which are responsible for daylight and color vision. In PRA-rcd2, the normal function and survival of these cells are compromised, causing a progressive decline in visual ability throughout the dog's life.
The earliest clinical sign of PRA-rcd2 is typically night blindness. Affected dogs may have difficulty seeing in low-light environments, appear hesitant when moving around in the dark, or struggle to navigate unfamiliar surroundings at night. As the disease progresses, vision loss becomes more noticeable during daylight hours as cone cells are also affected. Owners may observe their dog bumping into furniture, missing obstacles, showing reduced confidence during walks, or having difficulty locating toys and familiar objects. In advanced stages, complete blindness can occur. Although PRA-rcd2 leads to significant visual impairment, it is generally not painful, and many dogs adapt remarkably well to their loss of vision with appropriate care and environmental support.
The PRA-rcd2 DNA Health Test is designed to detect the specific genetic mutation associated with this inherited retinal disorder. Testing is simple, safe, and non-invasive, typically requiring either a cheek swab or blood sample. The collected sample is analyzed in a specialized laboratory to determine whether the dog carries the PRA-rcd2 mutation. Because the test examines DNA directly, it can be performed at any age, including in young puppies before clinical signs become apparent.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the PRA-rcd2 mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is not expected to develop the disease. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a high likelihood of developing PRA-rcd2-related retinal degeneration during its lifetime.
Genetic testing for PRA-rcd2 provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed breeding decisions that help reduce the occurrence of the disease while maintaining genetic diversity within the breed. By avoiding the mating of two carrier dogs, the risk of producing affected puppies can be significantly reduced.
For dog owners, knowledge of a dog’s genetic status allows for proactive eye health monitoring and regular veterinary ophthalmic examinations. While there is currently no cure to reverse retinal degeneration caused by PRA-rcd2, early diagnosis helps owners prepare for future vision changes and make adjustments that support their dog’s safety and quality of life.
The Progressive Retinal Atrophy (PRA-rcd2) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine eye health, and helps reduce the impact of inherited blindness in future generations. Through early detection and informed breeding strategies, breeders and owners can contribute to healthier dogs and improved long-term welfare.
